Program
zefamenib
Also written as “BN104 monotherapy”, “BN104 monotherapy - rp2d” and “BN104”.
Its studies are mostly in Precursor Cell Lymphoblastic Leukemia-Lymphoma, led by 2 companies.
Drug pageZefamenib: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioNova Pharmaceuticals (Shanghai)its history only | 10 open or running | phase 1since Dec 2, 2024 | Dec 2, 2024 | none ahead |
| Institut de Recherches Internationales Servier (I.R.I.S.) | 11 open or running | phase 2since Sep 6, 2023 | Sep 6, 2023 | Dec 2026phase 2 · NCT06052813 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Institut de Recherches Internationales Servier (I.R.I.S.) only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Sep 6, 2023First study: phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaFirst studyNCT06052813 · 66 enrolled · China
- Jul 10, 2025Named zefamenibINNProposed as its International Nonproprietary Name in WHO's List 133 · before, BN104
Ahead
- Dec 2026Primary completion: phase 2 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT06052813
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Institut de Recherches Internationales Servier (I.R.I.S.) leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06052813Precursor Cell Lymphoblastic Leukemia-Lymphoma · China | 2 | Active, not recruiting | Dec 2026 | 66 |
How it is read
Names in the registry
- “BN104 monotherapy”, 2 entries
- “BN104 monotherapy - rp2d”, 1 entry
- “BN104”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.